SynthesisPloS one2015
Excess costs of comorbidities in chronic obstructive pulmonary disease: a systematic review.
Synthesis in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Chronic obstructive pulmonary disease, lung function and risk of type 2 diabetes: a systematic review and meta-analysis of cohort studies.BMC pulmonary medicine · 2020Pooled it
- Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review.International journal of chronic obstructive pulmonary disease · 2020Pooled it
- Comorbid Influences on Generic Health-Related Quality of Life in COPD: A Systematic Review.PloS one · 2015Pooled it
- Integrating Disease Burden and Cost-Effectiveness for Value-Based Prioritisation of COPD Interventions: A Narrative Review.International journal of chronic obstructive pulmonary disease · 2026Review
- 20-year trends in excess costs of COPD.The European respiratory journal · 2025Article
- Incident Cardiometabolic Comorbidities in Smokers with/Without Chronic Obstructive Pulmonary Disease: A Long-Term Cohort Study.Journal of clinical medicine · 2024Article
- The Clinical Profile of Patients with COPD Is Conditioned by Age.Journal of clinical medicine · 2023Article
- Estimating health spending associated with chronic multimorbidity in 2018: An observational study among adults in the United States.PLoS medicine · 2023Observational
- Spatial distribution of unscheduled hospital admissions for chronic obstructive pulmonary disease in the central area of Asturias, Spain.BMC pulmonary medicine · 2023Article
- Outcomes associated with comorbid diabetes among patients with COPD exacerbation: findings from the ACURE registry.Respiratory research · 2021Article
- Review
- Multi-morbidities are Not a Driving Factor for an Increase of COPD-Related 30-Day Readmission Risk.International journal of chronic obstructive pulmonary disease · 2020Observational
- Trends in Hospitalization Expenditures for Acute Exacerbations of COPD in Beijing from 2009 to 2017.International journal of chronic obstructive pulmonary disease · 2020Article
- Direct and indirect costs of COPD progression and its comorbidities in a structured disease management program: results from the LQ-DMP study.Respiratory research · 2019Article
- Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: a randomised controlled proof-of-concept trial.ERJ open research · 2019Article
- Metabolic Syndrome in Early Chronic Obstructive Pulmonary Disease: Gender Differences and Impact on Exacerbation and Medical Costs.International journal of chronic obstructive pulmonary disease · 2019Article
- Health system costs for individual and comorbid noncommunicable diseases: An analysis of publicly funded health events from New Zealand.PLoS medicine · 2019Article
- Comparative analysis of medical expenditure with nebulized budesonide versus systemic corticosteroids in hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease in China.International journal of chronic obstructive pulmonary disease · 2019Observational
- Contributions of cardiovascular risk and smoking to chronic obstructive pulmonary disease (COPD)-related changes in brain structure and function.International journal of chronic obstructive pulmonary disease · 2019Article
- Economic burden of COPD in a Swedish cohort: the ARCTIC study.International journal of chronic obstructive pulmonary disease · 2018Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Comorbidities are often reported in patients with COPD and may influence the cost of care. Yet, the extent by which comorbidities affect costs remains to be determined.
objectivesTo review, quantify and evaluate excess costs of comorbidities in COPD.
methodsUsing a systematic review approach, Pubmed and Embase were searched for studies analyzing excess costs of comorbidities in COPD. Resulting studies were evaluated according to study characteristics, comorbidity measurement and cost indicators. Mark-up factors were calculated for respective excess costs. Furthermore, a checklist of quality criteria was applied.
resultsTwelve studies were included. Nine evaluated comorbidity specific costs; three examined index-based results. Pneumonia, cardiovascular disease and diabetes were associated with the highest excess costs. The mark-up factors for respective excess costs ranged between 1.5 and 2.5 in the majority of cases. On average the factors constituted a doubling of respective costs in the comorbid case. The main cost driver, among all studies, was inpatient cost. Indirect costs were not accounted for by the majority of studies. Study heterogeneity was high.
conclusionsThe reviewed studies clearly show that comorbidities are associated with significant excess costs in COPD. The inclusion of comorbid costs and effects in future health economic evaluations of preventive or therapeutic COPD interventions seems highly advisable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.